This study will evaluate the safety and pharmacokinetics of R348 in young, healthy males using a double-blind, placebo-controlled, single dose and multiple rising doses of R348. Results are expected in mid-2008.
Donald Payan, executive vice president and chief scientific officer at Rigel, said: “R348 enters the clinic at a time when Rigel’s product portfolio is demonstrating its potential contribution to the field of immunology. With R348 targeting T-cells and our oral syk kinase inhibitor, R788, targeting B-cells and other immune cells, Rigel has mounted a comprehensive assault on autoimmune disorders.”